[{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services | Lambda Therapeutic Research Ltd"},{"orgOrder":0,"company":"Jina Pharmaceuticals","sponsor":"Novum Pharmaceutical Research Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Jina Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services","highestDevelopmentStatusID":"10","companyTruncated":"Jina Pharmaceuticals \/ Novum Pharmaceutical Research Services"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Quantum Leap Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Quantum Leap Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Quantum Leap Healthcare"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"InClin","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Endoxifen","moa":"ER aplha","graph1":"Oncology","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Atossa Therapeutics \/ InClin","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ InClin"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Societal CDMO \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Atossa Therapeutics \/ Karolinska Institutet","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Karolinska Institutet"},{"orgOrder":0,"company":"Atossa Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Undisclosed","graph2":"Phase II","graph3":"Atossa Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Atossa Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Atossa Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Endoxifen

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : (Z)-endoxifen is a highly potent Selective Estrogen Receptor Modulator (SERM) with demonstrated ability to inhibit—and potentially degrade—estrogen receptors.

                          Product Name : (Z)-Endoxifen

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 14, 2025

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Jina Pharmaceuticals

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Jina Pharmaceuticals

                          Country arrow
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 23, 2024

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Novum Pharmaceutical Research Services

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.

                          Product Name : (Z)-Endoxifen

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 06, 2023

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Endoxifen (z-endoxifen) is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.

                          Product Name : (Z)-Endoxifen

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 28, 2023

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Quantum Leap Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...

                          Product Name : (Z)-Endoxifen

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 23, 2023

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Atossa Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : (Z)-endoxifen is the most active metabolite of the FDA approved selective estrogen receptor modulator (SERM), tamoxifen. It has demonstrated that the anti-estrogenic effects and is being evaluated for ER+/HER2+ breast cancer.

                          Product Name : (Z)-Endoxifen

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 21, 2023

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Quantum Leap Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 07, 2022

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : InClin

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 05, 2021

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Endoxifen, an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. Endoxifen administered to breast cancer patients prior to surgery.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 06, 2021

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 05, 2020

                          Lead Product(s) : Endoxifen

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase II

                          Sponsor : Karolinska Institutet

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank